Maria Forero, MPH

Revolutionizing dermatology, SKNV stands as a pioneer in customized solutions. Our FDA-registered outsourcing facility meticulously produces over 120 specialized Rx medicines, ensuring reliability and customized medications, all manufactured without questionable ingredients. Dermatologists, empowered by SKNV, can select from a menu of solutions for diverse skin conditions, and a variety of vehicles, including creams, gels, and ointments. The freedom to write prescriptions as they see fit is a hallmark of SKNV, eliminating the tedious process of prior authorizations. Dermatologists confidently tackle dermatological challenges while maintaining a balance between efficacy and budget for the patient. SKNVs commitment to removing extra preservatives, such as parabens, dyes, fillers, or excipients, sets us apart. With a reputation built on trust, SKNV operates from an FDA-Registered 503B Outsourcing Facility, delivering reliable and high-quality medications. Dermatologists looking to elevate their practice and provide customized solutions tailored for their patients skin and the world they live in, need look no further than SKNV!

Venture-backed startup developing first-in-class predictive biomarker tests to harness high-efficacy, low-toxicity antifibrotic drugs to prevent cancer progression. MeCo Diagnostics traces its origins to the oldest observation in cancer biology: tumors often grow stiffer than surrounding tissue, leading to a palpable lump, which is the most common indicator of disease. Not all cancer cells are responsive to increased stiffness of their microenvironment, but those that are become “mechanically conditioned,” akin to deadly, microscopic wind-up machines that are destined to wreak havoc as they spread throughout the body. Mechanical conditioning as a problem dictates mechanical deconditioning as a solution; fortunately, there are FDA-approved antifibrotic drugs which can be repurposed for this need. This serendipity has empowered us to develop a commercially viable, biomarker-enabled drug repurposing approach that synergizes with conventional neoadjuvant treatment. Our lead asset, the MeCo Score, has been rigorously validated in 4 independent clinical studies of breast cancer comprised of over 4000 patients total, in partnership with oncologists at Cleveland Clinic, the University of Arizona, and the Spanish National Cancer Research Center. Ultimately, we aim to reduce breast, prostate, and colorectal cancer burden in patients before primary surgery, leading to higher rates of lifelong remission. Since our proof of concept lead asset (MeCo Score) matches patients to a generic-emergent drug, the cost of targeted antifibrotic therapy will soon be >10X cheaper than any other targeted therapy for breast cancer in history. Patients will benefit from reduced co-insurance costs, while payers will benefit from reduced expenditures. It’s a win-win for healthcare stakeholders. For more information on our team, our research, or our current fundraising round, please reach out.

We are a bioinformatics-based precision medicine platform company translating patient-specific and population-based medical big data into novel pharmacological clinical treatment decision support products and services. We offer a proprietary technology, the PredictMed Platform, designed to help clinicians and health systems optimize precision in the selection of appropriate medications, drug combinations and dosages that improve each patients health, while also reducing adverse reactions. Our PrecīsMed platform represents a significant step forward in accurately assessing a patient’s complete medication profile. Physicians can finally see the full spectrum of medications present in the patient, and identify appropriate dosing levels for therapeutic effectiveness. PrecīsMed can accurately assess prescribing trends, medication adherence and EHR coverage, as well as define medication concentrations in patients with comorbid disorders.

MF7 Ventures is a Miami- based, early venture capital fund focused on emerging healthcare technologies delivering improved patient outcomes and cost savings to the supporting health system.

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology. Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to recruitment@clicktherapeutics.com. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.

PharmStars Ventures is a venture capital fund investing in early ownership of digital health and AI companies aligned with pharma’s most urgent needs. The fund leverages proprietary access, embedded diligence, and a disciplined investment strategy to invest ahead of traditional VC price discovery. PharmStars Ventures is actively deploying capital across a global portfolio of pharma-aligned startups shaping the future of healthcare and life sciences.

Springboard accelerates the growth of entrepreneurial companies led by women through access to essential resources and a global community of experts. We are a leading network of influencers, investors, and innovators dedicated to building high-growth companies led by women who are transforming industries. The measure of our success is in the results. Since we started in 2000, 950+ Springboard portfolio companies have created more than $76B in value, 28 IPOs, and 10 unicorns.

Revolutionizing dermatology, SKNV stands as a pioneer in customized solutions. Our FDA-registered outsourcing facility meticulously produces over 120 specialized Rx medicines, ensuring reliability and customized medications, all manufactured without questionable ingredients. Dermatologists, empowered by SKNV, can select from a menu of solutions for diverse skin conditions, and a variety of vehicles, including creams, gels, and ointments. The freedom to write prescriptions as they see fit is a hallmark of SKNV, eliminating the tedious process of prior authorizations. Dermatologists confidently tackle dermatological challenges while maintaining a balance between efficacy and budget for the patient. SKNVs commitment to removing extra preservatives, such as parabens, dyes, fillers, or excipients, sets us apart. With a reputation built on trust, SKNV operates from an FDA-Registered 503B Outsourcing Facility, delivering reliable and high-quality medications. Dermatologists looking to elevate their practice and provide customized solutions tailored for their patients skin and the world they live in, need look no further than SKNV!

AiCure is an AI and advanced data analytics company that monitors patient behavior and enables remote patient engagement in clinical trials. AiCure improves predictability of study timelines, reduces costs and accelerates timelines through remote patient engagement and assessments, including measuring digital biomarkers and real-time monitoring of patient dosing. Founded in 2010 and funded by the National Institutes of Health (NIH) and leading institutional investors, AiCure has more than 65 issued patents and works with global clients in over 30 countries. AiCure is globally recognized and is a recipient of the Scrip Award, AI 100 and Digital Health 150. For more information, please visit www.aicure.com.

Accelmed Partners is a lower middle-market private equity firm focused on acquiring and investing in U.S. commercial-stage HealthTech companies. For more than a decade, we have leveraged our deep HealthTech industry experience, operational and financial expertise, and strong relationships to help management teams at companies across the medical device, tools, diagnostics, digital health and tech-enabled services sectors position their businesses for future growth and success. Our ideal partners share our values of integrity, transparency and tenacity, directed toward leveraging technology to improve patient outcomes, reduce costs and increase efficiency throughout the healthcare system. We currently manage over $630 million of equity capital and are actively investing out of our second private equity fund, Accelmed Partners II.